Posted on Thursday 9 July 2015 by Ulster Business
Patrick Henry, Head of Randox Biosciences, with Dr Rachana Thapliyal of Randox Biosciences
An Antrim company has created 30 new jobs in its new research and development department.
The posts at clinical diagnostics company Randox will be based in its new Randox Biosciences division.
It is focused on discovery, drug development and companion diagnostics and is the result of the merger and expansion of four existing business units; Life Sciences, Pharma Sciences, Research and Molecular.
Around 15 of the roles have already been filled and a further 15 will join the team of 300 scientists and engineers in the division which supplies products and services to universities, genetics labs and the pharmaceutical industry across the globe.
Patrick Henry, Head of Randox Biosciences, said export will be a key target.
“Our focus is on targeting the thriving personalised medicine market which at its heart relies on ‘precision medicine’ enabling technology and tests to tailor healthcare solutions to the right patients at the right time,” he said. “Led by our dedicated research scientists, we offer advanced products, for use in academic research enabling new scientific discoveries and in pharma companies for their drug development and clinical trials.
Randox MD, Dr Peter FitzGerald said innovation is key to the business.
“Research and development is fundamental to the creation of new products and we recognise its importance. In 2014-15 we invested £15million into R&D, our most significant spend on this core function to date. This investment has allowed us to establish the Randox Biosciences division, which will act as a road map for our R&D, taking our tests and technology to new markets across the world.